227 related articles for article (PubMed ID: 36163324)
1. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J
Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
3. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
4. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
[TBL] [Abstract][Full Text] [Related]
5. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
[TBL] [Abstract][Full Text] [Related]
8. Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Kristeleit RS; Moore KN
Ann Oncol; 2022 Oct; 33(10):989-991. PubMed ID: 35964823
[No Abstract] [Full Text] [Related]
9. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
10. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
11. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
13. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
15. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
[TBL] [Abstract][Full Text] [Related]
17. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
18. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
